TP53 and neoplasm: TP53 mutations are observed in 60% of PLPS patients [26], deletion of 13q14.2-5 (containing the tumor-suppressor gene RB1) in up to 50% [21] and loss of tumor the suppressor-gene NF1 in 5% of patients [30].